ANXA1 and myocardial infarction: Upregulation of Anxa1 in vivo, improves atherosclerosis (decreased lesion size, inflammation, improved plaque stability) [45,46,47], myocardial infarction (decreased infarct size, inflammation and increased survival) [48,49,50,51] and stroke (decreased infarct size, inflammation) [52,53,54,55].